Silevertinib and chemo for a type of glioblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, silevertinib, combined with temozolomide (a chemotherapy) for people with a newly diagnosed glioblastoma that has certain genetic markers. It aims to see if this combination works better than standard treatment for tumors with these specific features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a newly diagnosed glioblastoma that has not been treated before (only surgery and standard radiation/chemotherapy are allowed).
- Your tumor must have a specific genetic change called EGFRvIII (or another EGFR alteration for the first part).
- The tumor must have an unmethylated MGMT promoter, which means it is less likely to respond to temozolomide alone.
- You must have completed radiation therapy at least 4 weeks ago, and an MRI must show that the tumor has not grown.
- You cannot have received any other experimental treatments or targeted drugs for glioblastoma before this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares the usual treatment (radiation plus a chemotherapy drug called temozolomide) with the same treatment plus an extra drug called lenvatinib. The goal is to see if adding lenvatinib helps people with a certain type of glioblastoma live longer or keep the tumor from growing back.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.